These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 7690928)

  • 21. Dispensability of p53 degradation for tumorigenicity and decreased serum requirement of human papillomavirus type 16 E6.
    Inoue T; Oka K; Yong-Il H; Vousden KH; Kyo S; Jing P; Hakura A; Yutsudo M
    Mol Carcinog; 1998 Mar; 21(3):215-22. PubMed ID: 9537653
    [TBL] [Abstract][Full Text] [Related]  

  • 22. p53-independent abrogation of a postmitotic checkpoint contributes to human papillomavirus E6-induced polyploidy.
    Liu Y; Heilman SA; Illanes D; Sluder G; Chen JJ
    Cancer Res; 2007 Mar; 67(6):2603-10. PubMed ID: 17363579
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A plant lignan, 3'-O-methyl-nordihydroguaiaretic acid, suppresses papillomavirus E6 protein function, stabilizes p53 protein, and induces apoptosis in cervical tumor cells.
    Allen KL; Tschantz DR; Awad KS; Lynch WP; DeLucia AL
    Mol Carcinog; 2007 Jul; 46(7):564-75. PubMed ID: 17393435
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The presence of human papillomavirus-16/-18 E6, p53, and Bcl-2 protein in cervicovaginal smears from patients with invasive cervical cancer.
    Pillai MR; Halabi S; McKalip A; Jayaprakash PG; Rajalekshmi TN; Nair MK; Herman B
    Cancer Epidemiol Biomarkers Prev; 1996 May; 5(5):329-35. PubMed ID: 9162297
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HPV-18 E6 inhibits p53 DNA binding activity regardless of the oligomeric state of p53 or the exact p53 recognition sequence.
    Thomas M; Massimi P; Banks L
    Oncogene; 1996 Aug; 13(3):471-80. PubMed ID: 8760288
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Telomerase activation by the E6 gene product of human papillomavirus type 16.
    Klingelhutz AJ; Foster SA; McDougall JK
    Nature; 1996 Mar; 380(6569):79-82. PubMed ID: 8598912
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HPV 16-E6-mediated degradation of intrinsic p53 is compensated by upregulation of p53 gene expression in normal cervical keratinocytes.
    Kawamata Y; Mitsuhashi A; Unno Y; Kado S; Shino Y; Uesugi K; Eguchi O; Ishii J; Seki K; Sekiya S; Shirasawa H
    Int J Oncol; 2002 Sep; 21(3):561-7. PubMed ID: 12168100
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Temperature-sensitive mutants of p53 associated with human carcinoma of the lung.
    Medcalf EA; Takahashi T; Chiba I; Minna J; Milner J
    Oncogene; 1992 Jan; 7(1):71-6. PubMed ID: 1741167
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Alternatively spliced HPV-18 E6* protein inhibits E6 mediated degradation of p53 and suppresses transformed cell growth.
    Pim D; Massimi P; Banks L
    Oncogene; 1997 Jul; 15(3):257-64. PubMed ID: 9233760
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Human papillomavirus type 16 E6 inactivation of p53 in normal human mammary epithelial cells promotes tamoxifen-mediated apoptosis.
    Seewaldt VL; Mrózek K; Dietze EC; Parker M; Caldwell LE
    Cancer Res; 2001 Jan; 61(2):616-24. PubMed ID: 11212259
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The DNA binding activity of wild type p53 is modulated by blocking its various antigenic epitopes.
    Wolkowicz R; Elkind NB; Ronen D; Rotter V
    Oncogene; 1995 Mar; 10(6):1167-74. PubMed ID: 7535417
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative analysis of 19 genital human papillomavirus types with regard to p53 degradation, immortalization, phylogeny, and epidemiologic risk classification.
    Hiller T; Poppelreuther S; Stubenrauch F; Iftner T
    Cancer Epidemiol Biomarkers Prev; 2006 Jul; 15(7):1262-7. PubMed ID: 16835321
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HPV-16 E6 oncoprotein induces mutations via p53-dependent and -independent pathways.
    Kim HJ; Guo W; Park NH
    Oncol Rep; 2000; 7(4):707-12. PubMed ID: 10854530
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Human papillomavirus type 16 E6 oncogene and expression of P53, RB and PCNA in human cervical carcinoma].
    Bian J; Yu X; Dong J; Zhao W; Zhou Y; Luan Y
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 1997 Sep; 11(3):271-3. PubMed ID: 15617346
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HPV-18 E6*I protein modulates the E6-directed degradation of p53 by binding to full-length HPV-18 E6.
    Pim D; Banks L
    Oncogene; 1999 Dec; 18(52):7403-8. PubMed ID: 10602499
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Proteasomal degradation of p53 by human papillomavirus E6 oncoprotein relies on the structural integrity of p53 core domain.
    Bernard X; Robinson P; Nominé Y; Masson M; Charbonnier S; Ramirez-Ramos JR; Deryckere F; Travé G; Orfanoudakis G
    PLoS One; 2011; 6(10):e25981. PubMed ID: 22046250
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interaction of the human papillomavirus type 16 E6 oncoprotein with wild-type and mutant human p53 proteins.
    Scheffner M; Takahashi T; Huibregtse JM; Minna JD; Howley PM
    J Virol; 1992 Aug; 66(8):5100-5. PubMed ID: 1321290
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oligomerisation of full length p53 contributes to the interaction with mdm2 but not HPV E6.
    Marston NJ; Jenkins JR; Vousden KH
    Oncogene; 1995 May; 10(9):1709-15. PubMed ID: 7753547
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biological activities of p53 mutants in Burkitt's lymphoma cells.
    Vousden KH; Crook T; Farrell PJ
    J Gen Virol; 1993 May; 74 ( Pt 5)():803-10. PubMed ID: 8492087
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mutational analysis of human papillomavirus type 16 E6 demonstrates that p53 degradation is necessary for immortalization of mammary epithelial cells.
    Dalal S; Gao Q; Androphy EJ; Band V
    J Virol; 1996 Feb; 70(2):683-8. PubMed ID: 8551603
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.